文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

PSMA PET/CT引导下挽救性全盆腔放疗治疗复发前列腺癌的肿瘤学结局

Oncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-04-06

本研究为单中心回顾性分析,纳入149例根治性前列腺切除术后生化复发且PSMA PET/CT提示盆腔淋巴结转移的患者,接受PSMA PET/CT引导下挽救性全盆腔放疗联合2–3年ADT。中位随访54个月,5年bPFS、MFS、TFS、OS和CSS分别为69.3%、79.0%、78.5%、91.7%和97.5%;生化进展37例,野内复发罕见,以野外淋巴结复发为主。

要点

  • PSMA PET/CT引导sWPRT联合ADT后5年bPFS为69.3%,OS为91.7%。
  • 生化进展者中野内复发仅1/37,野外淋巴结复发29/37。
  • sWPRT前PSA较高和ADT疗程较长是生化进展的独立预测因素。

核心结论

  • PSMA PET/CT引导的挽救性全盆腔放疗联合ADT在根治性前列腺切除术后生化复发患者中提供良好的野内肿瘤控制和5年肿瘤学结局。
  • sWPRT前PSA和ADT疗程是bPFS的显著预测因素。

研究设计与样本

  • 单中心回顾性分析纳入149例根治性前列腺切除术后生化复发患者,于2018–2022年接受PSMA PET/CT引导sWPRT联合2–3年ADT。
  • sWPRT适用于盆腔PSMA阳性淋巴结≤6个的生化复发患者,或既往pN1疾病且PSMA阴性的患者。

主要发现

  • 中位随访54个月,5年bPFS、MFS、TFS、OS和CSS分别为69.3%、79.0%、78.5%、91.7%和97.5%。
  • PSMA阴性与PSMA阳性亚组之间结局无差异。
  • 37例(25%)发生生化进展,野内复发罕见(1/37),以野外淋巴结复发为主(29/37)。
  • sWPRT前PSA较高(HR=3.88,p=0.021)和ADT疗程较长(HR=0.92,p<0.001)独立预测生化进展。

关键数值与推荐

  • sWPRT前PSA较高与生化进展风险升高独立相关(HR=3.88,p=0.021)。
  • ADT疗程较长与生化进展风险降低独立相关(HR=0.92,p<0.001)。
  • sWPRT入选条件为盆腔PSMA阳性淋巴结≤6个,或PSMA阴性但既往pN1。

临床怎么用

  • 对根治性前列腺切除术后生化复发且PSMA PET/CT提示盆腔淋巴结转移(≤6个)的患者,可考虑PSMA PET/CT引导sWPRT联合2–3年ADT。
  • sWPRT前PSA较高提示生化进展风险较高,ADT疗程较长与bPFS改善相关,可据此评估风险与治疗强度。
  • 野外淋巴结复发为主而野内复发罕见,提示需关注盆腔外淋巴结随访与后续挽救策略。

局限性

  • 单中心回顾性设计可能引入选择偏倚。
  • 样本量149例,随访中位54个月,长期结局仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In patients with biochemical recurrence (BCR) after radical prostatectomy (RP), prostate-specific membrane antigen (PSMA) PET/CT can detect early pelvic lymph node metastases, yet optimal management of these recurrences remains unclear. This study evaluates oncological outcomes of patients with BCR after RP and (confirmed or suspected) pelvic lymph node metastases who were treated with PSMA PET/CT-guided salvage whole pelvis radiotherapy (sWPRT) and Androgen Deprivation Therapy (ADT). MATERIALS AND METHODS: This single-centre retrospective analysis included 149 patients undergoing sWPRT and 2-3 years ADT after PSMA PET/CT for BCR following RP ± ePLND (2018-2022). sWPRT was offered to BCR patients with ≤ 6 pelvic PSMA-positive nodes, or to PSMA-negative patients with prior pN1 disease. Outcomes included biochemical progression-free survival (bPFS), metastasis-free survival (MFS), treatment-free survival (TFS), overall survival (OS), and cancer-specific survival (CSS). Multivariate Cox regression identified predictors of biochemical progression. Recurrence locations on PSMA PET/CT were recorded and correlated with radiotherapy fields. RESULTS: After a median 54-month follow-up, 5-year bPFS, MFS, TFS, OS and CSS were; 69.3%, 79.0%, 78.5%, 91.7% and 97.5%. Outcomes did not differ between PSMA-negative and PSMA-positive subgroups. Biochemical progression occurred in 37 patients (25%), with rare in-field recurrences (1/37) and predominantly out-field nodal recurrences (29/37). Higher pre-sWPRT PSA (HR = 3.88, p = 0.021) and longer ADT duration (HR = 0.92, p < 0.001) independently predicted biochemical progression. CONCLUSION: PSMA PET/CT-guided sWPRT with ADT provides good in-field tumour control and good 5-year oncological outcomes in patients with BCR following RP. PSA prior to sWPRT and ADT duration were significant predictors for bPFS.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zuur LG, Jansen A, van der Graaf SH, et al. Oncological outcomes following PSMA PET/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer. Clin Transl Radiat Oncol. 2026. PMID: 42005712. doi:10.1016/j.ctro.2026.101161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。